The Risk of Treatment-Resistant High Blood Pressure
High blood pressure, also known as hypertension, is the single most common contributor to death worldwide, affecting approximately 1.2 billion people globally.1
Many patients with high blood pressure respond well to lifestyle changes and pharmaceutical therapy, but unfortunately a large segment of this population isn’t able to get their blood pressure under control even when taking three or more blood pressure medications. Research suggests that 28 percent of treated hypertensive individuals are considered resistant to treatment.2 Additionally, these patients have a threefold increase in risk of cardiovascular events compared to individuals with controlled high blood pressure.*
We’re Taking Back Control
It has become clear to the medical community that more effective treatment strategies are critically needed. The prevalence of treatment-resistant high blood pressure will only increase given an aging population with more obesity and related complications, including type 2 diabetes and chronic kidney disease.
Power Over Pressure
Developed by a team of global experts in hypertension, Power Over Pressure is a global campaign to raise awareness of the challenges faced by the nearly 100 million people worldwide who are living with treatment-resistant high blood pressure (patients with persistently high blood pressure [greater than 140/90 mm Hg] despite treatment with three or more medications). To understand this substantial and growing population of at-risk patients, Power Over Pressure conducted a global study of more than 4,500 uncontrolled hypertension patients in eight countries. Power Over Pressure is endorsed by both the European Society of Hypertension (ESH) and the American Society of Hypertension, Inc. (ASH).
If you've been struggling to control your blood pressure despite lifestyle changes, and are taking three or more medications, you are not alone. This educational site will help you learn more about treatment-resistant high blood pressure and how to take better control of it.
The program is supported by Medtronic, Inc., a global leader in medical technology.* Additionally, these patients have a threefold increase in risk of cardiovascular events compared to individuals with controlled high blood pressure.
- Persell, Stephen D. Prevalence of Resistant Hypertension in the United States, 2003-2008. Hypertension 57.6 (2011): 1076-1080.
- Egan, Brent M., et al. Uncontrolled and Apparent Treatment-Resistant Hypertension in the United States, 1988-2008. Circulation 124.9 (2011): 1046-1058.